Literature DB >> 10909414

Anti-beta 2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells.

A Kornberg1, Y Renaudineau, M Blank, P Youinou, Y Shoenfeld.   

Abstract

Anti-beta 2-glycoprotein I antibodies bind to endothelial cells through beta 2-GPI. The antibodies are present in patients with systemic lupus erythematosus and antiphospholipid syndrome and are associated with the pathogenesis of the disease. Anti-endothelial cell antibodies that react with constitutive antigens on ECs are present in patients with vasculiditis and other diseases. Both types of antibodies can activate ECs. Frequent findings in APLS and vasculitis are fibrin deposits and thromboembolic phenomena. These indicate that the coagulation system is activated. However, the mechanism of activation is not clear. ECs generate tissue factor upon stimulation with various substances. In the present study we report that monoclonal anti-beta 2-GPI antibodies and AECAs, derived from a patient with primary APLS and a patient with Takayasu's arteritis, respectively, induce a potent tissue factor in ECs. The production of TF activity, TF antigen and TF mRNA is dose and time dependent. The TF activity was induced also by F(ab)2 but not by Fc fragments and was abolished completely by pre-incubation with ant-TF antibodies. The TF that is induced in ECs by AECAs with and without beta 2-GPI specificity may activate the coagulation and thereby play a major role in the pathogenesis of fibrin deposition and thrombus formation in diseases that are associated with the presence of these antibodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10909414

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  11 in total

Review 1.  Antiendothelial cell antibodies in vasculitis and connective tissue disease.

Authors:  C Belizna; A Duijvestijn; M Hamidou; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

2.  The HELLP syndrome, antiphospholipid antibodies, and syndromes.

Authors:  Ronald A Asherson; Claudio Galarza-Maldonado; Jose Sanin-Blair
Journal:  Clin Rheumatol       Date:  2007-10-03       Impact factor: 2.980

3.  Pregnancy and catastrophic antiphospholipid syndrome.

Authors:  Jose A Gómez-Puerta; Jose Sanin-Blair; Claudio Galarza-Maldonado
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Non-DNA-binding antibodies in patients with lupus nephritis could recognize membrane proteins of glomerular mesangial cells.

Authors:  Hui Du; Min Chen; Ying Zhang; Ming-Hui Zhao
Journal:  J Clin Immunol       Date:  2006-04-18       Impact factor: 8.317

Review 5.  Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.

Authors:  Laurent Simonin; Elisabeth Pasquier; Christophe Leroyer; Divi Cornec; Julie Lemerle; Boutahar Bendaoud; Sophie Hillion; Jacques-Olivier Pers; Francis Couturaud; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 6.  Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome.

Authors:  Guillermina Girardi
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

7.  Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression.

Authors:  F Conti; M Sorice; A Circella; C Alessandri; V Pittoni; B Caronti; C Calderaro; T Griggi; R Misasi; G Valesini
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

Review 8.  Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases.

Authors:  Philippe Guilpain; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

9.  Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I.

Authors:  Jose M Morales; Jose Angel Martinez-Flores; Manuel Serrano; Maria José Castro; Francisco Javier Alfaro; Florencio García; Miguel Angel Martínez; Amado Andrés; Esther González; Manuel Praga; Estela Paz-Artal; Antonio Serrano
Journal:  J Am Soc Nephrol       Date:  2014-07-28       Impact factor: 10.121

10.  Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.

Authors:  N K Singh; A Gupta; Dibya R Behera; D Dash
Journal:  Rheumatol Int       Date:  2013-03-22       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.